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Abstract 34 
Cholesterol crystals (CC) play an essential role in the formation of atherosclerotic plaques. CC 35 
activate the classical and the alternative complement pathways, but the role of the lectin pathway is 36 
unknown. We hypothesized that the pattern recognition molecules (PRM) from the lectin pathway 37 
bind CC and functions as an upstream innate inflammatory signal in the pathophysiology of 38 
atherosclerosis. We investigated the binding of the PRMs mannose-binding lectin (MBL), ficolin-1, 39 
ficolin-2, and ficolin-3, the associated serine proteases, and complement activation products to CC 40 
in vitro using recombinant proteins, specific inhibitors as well as deficient and normal sera. In 41 
addition we examined the deposition of ficolin-2 and MBL in human carotid plaques by 42 
immunohistochemistry and fluorescence microscopy.  The results showed that the lectin pathway 43 
was activated on CC by binding of ficolin-2 and MBL in vitro, resulting in activation and 44 
deposition of complement activation products. MBL bound to CC in a calcium dependent manner 45 
while ficolin-2 binding was calcium independent. No binding was observed for ficolin-1 or ficolin-46 
3. MBL and ficolin-2 were present in human carotid plaques and binding of MBL to CC was 47 
confirmed in vivo by immunohistochemistry, showing localization of MBL around CC clefts. 48 
Moreover, we demonstrated that IgM, but not IgG bound to CC in vitro and that C1q binding was 49 
facilitated by IgM.  50 
In conclusion our study demonstrates that PRMs from the lectin pathway recognize CC and 51 
provides evidence for an important role for this pathway in the inflammatory response induced by 52 
CC in the pathophysiology of atherosclerosis. 53 
54 
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Introduction 55 
Vascular diseases arising from atherosclerosis are among the leading causes of morbidity and death 56 
in western countries. Cholesterol crystals (CC) appear early in the development of atherosclerosis 57 
and play an essential role in the formation of atherosclerotic plaques by inducing inflammation and 58 
functioning as an endogenous danger signal (1). Cholesterol is almost water insoluble, but it is 59 
solubilized in vivo in lipid bilayers or micelle systems, where it serves as a stabilizing component of 60 
cell membranes and a precursor of bile salts and steroid hormones. Unbalanced cholesterol 61 
metabolism results in undesired in vivo precipitation of CC. Cholesterol crystallizes in a bilayer 62 
structure with an end-for-end arrangement of approximately parallel molecules (2). CC are known 63 
to activate the complement system (3-5) and induce complement dependent inflammasome 64 
activation and cytokine release in phagocytes in vitro (1,6,7).  65 
 66 
Activation of the complement system is an important part of the innate immune response and is 67 
initiated when pattern recognition molecules (PRMs) recognize pathogen associated molecular 68 
patterns on foreign cells or damaged host cells.  The effector functions of the complement system 69 
include elimination of invading pathogens,  regulation of adaptive immunity, and maintenance of 70 
tissue homeostasis (8). The complement system is activated through three different pathways: the 71 
classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP).  72 
 73 
The PRM mannose-binding lectin (MBL) is a soluble collectin, that is able to activate the LP (9,10). 74 
MBL recognizes a wide variety of microorganisms and altered self via a carbohydrate recognition 75 
domain (CRD), and distinguish between normally present self-structures and foreign structures, 76 
including microbes and damaged self, based on the orientations of hydroxyl groups on 77 
carbohydrates (11).  78 
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The LP can also be activated by ficolins (12-14). Three types of ficolins have been characterized in 79 
humans; ficolin-1 (M-ficolin), ficolin-2 (L-ficolin), and ficolin-3 (H-ficolin). The ficolins are 80 
multimeric macromolecules, structurally and functionally related to collectins. Ficolin-1, ficolin-2, 81 
and ficolin-3 are found in serum (15-17), with ficolin-1 being the least abundant (15). Ficolins 82 
primarily recognize acetylated compounds via the fibrinogen like domain, such as N-acetyl-D-83 
glucosamine (GlcNAc) and acetylated BSA (AcBSA) (18,19). The LP recognition molecules have 84 
also been shown to recognize and participate in the removal of altered and dying host cells (20-23). 85 
PRMs of the LP are found in complexes with the MBL/ficolin-associated serine proteases 86 
(MASPs). Three catalytically active serine proteases; MASP-1, MASP-2, and MASP-3, and two 87 
alternative splice products; MAP-1 (MAp44) and sMAP (MAp19) are known (24). 88 
 89 
The CP is activated by direct binding of the PRM C1q to various structures and ligands on 90 
pathogens or apoptotic cells, or indirectly via other molecules such as immunoglobulins or C-91 
reactive protein. The AP is activated by spontaneous hydrolysis of the internal C3 thioester in the 92 
fluid phase or directly on foreign surfaces that are not protected against complement activation (25). 93 
In addition, the AP functions as an amplification loop, enhancing CP and/or LP initiated 94 
complement activation substantially. 95 
 96 
Complement activation and deposition of complement activation products occur both in 97 
experimental and human atherosclerosis (26-31). Monohydrate CC, similar to those found in 98 
atherosclerotic plaques, activate the CP and the AP (3-5,7). CC activate the CP through binding of 99 
C1q, but whether C1q binds directly to the CC or indirectly via immunoglobulins, C-reactive 100 
protein, or other molecules is still not clear. C1q is present in atherosclerotic lesions and has been 101 
shown to play a protective role in early atherosclerotic development in a C1q deficient mouse 102 
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model of atherosclerosis (32). However, in this model, C5b-9 deposition in aortic lesions was not 103 
abolished suggesting involvement of the LP and/or the AP. 104 
 105 
Whether the LP is involved in the local inflammation initiated by CC in the pathophysiology of 106 
atherosclerosis is not known, but MBL is present in atherosclerotic lesions and MBL gene variants 107 
leading to functional defects of MBL have been associated with myocardial infarction (33) and 108 
severity of atherosclerosis (34,35). Cholesterol compounds have been shown to differ in their 109 
complement activation ability, depending on the position as well as the number of hydroxyl groups 110 
(4). Since MBL and the ficolins bind hydroxyl groups, we hypothesized that MBL and ficolins bind 111 
monohydrate CC similar to those found in atherosclerotic plaques, and functions as an upstream 112 
innate inflammatory signal in the pathophysiology of atherosclerosis. Thus, the objectives of this 113 
study were to investigate the binding of the pattern recognition molecules from the lectin 114 
complement pathway (MBL, ficolin-1, -2, and -3) and the associated serine proteases (MASPs) to 115 
cholesterol crystals in vitro and in vivo in human carotid plaques, and to determine the role of the 116 
lectin pathway in the complement activation initiated by cholesterol crystals. Furthermore, the 117 
purpose was to clarify if the C1q mediated classical pathway activation on cholesterol crystals was 118 
initiated through direct binding of C1q or if C1q bound indirectly via IgG, IgM or both. 119 
120 
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Methods121 
Reagents 122 
Ultrapure cholesterol (C8667), 1-propanol (279544), RPMI 1640 medium , Erythrosine, HSA 123 
(A9731), BSA (A2153), EGTA (E3889), GlcNAc (A8625), D-Mannose (M6020), and D-(+)-124 
Galactose (G0750) were purchased from Sigma-Aldrich. EDTA (324503) was purchased from 125 
Calbiochem. Glycergel mounting medium (C0563), Dako EnVision Plus autostainer, Polymer 126 
EnVision-HRP anti-Mouse, DAB+ Chromogen solution, Dako wash buffer (S3006), and Serum 127 
Free Protein block (X0909) was purchased from DAKO, Denmark. Purified human C4 (A108) and 128 
purified human C1q (A099) were purchased from Complement Technology, Denmark. Serum-free 129 
medium Chinese hamster ovary (CHO) CD1 was from Lonza, Denmark. Tissue-Tek O.C.T. 130 
compound was from Sakura, Japan. Haematoxylin and Saffron was from Chemi – Teknik AS, 131 
Norway. Alexa647 anti-mouse IgG Thermo Fisher Scientific, USA and Mowiol 4-88 was from 132 
Hoechst, Germany.  133 
 134 
The following reagents were used as complement inhibitors: C5 inhibitor; eculizumab (Soliris, 135 
Alexion), C3 inhibitory peptide; compstatin Cp40 (36),  C1q inhibitory mAb mouse anti-human 136 
C1q clone 85 (IgG1) (MW1828, Sanquin), MASP-1 inhibitor SGMI-1 (37), and MASP-2 inhibitor 137 
SGMI-2 (37). The following antibodies were used: FITC conjugated polyclonal rabbit anti-rat Ab 138 
(F1763, Sigma-Aldrich), FITC conjugated polyclonal goat anti-rabbit Ab (F1262, Sigma-Aldrich), 139 
FITC conjugated polyclonal goat anti-mouse Ab (F0479, DAKO), mouse IgG1κ isotype control 140 
(BD Bioscience), mouse IgG2a isotype control (BD Bioscience), rabbit IgG isotype control 141 
(Invitrogen), rat IgG1κ isotype control (BD Bioscience), mouse anti-human MBL mAb 131-10 142 
(IgG1κ) (Bioporto Diagnostics), mouse anti-human MBL 131-01 (IgG1κ) (Bioporto Diagnostics), 143 
MBL inhibitory mAb mouse anti-human MBL 3F8 (IgG1) (38), MBL binding mAb mouse anti-144 
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human MBL 1C10 (IgG2) (39), rat anti-human MASP-2 mAb 8B5 (HM2190, Hycult biotech), 145 
mouse anti-human complement component C5b-9 mAb (IgG2a) (011-01, Antibody Shop), 146 
polyclonal rabbit anti-human C4c Ab (Q0369, DAKO), polyclonal rabbit anti-human C1q (A0136, 147 
DAKO), rabbit anti-human IgM (0425, DAKO) and rabbit anti-human IgG (0423, DAKO). In 148 
house produced monoclonal antibodies: mouse anti-human ficolin-1 FCN106 (IgG1κ) (40), mouse 149 
anti-human ficolin-2 FCN219 (IgG2a) (16), ficolin-2 inhibitory Ab mouse anti-human ficolin-2 150 
FCN212 (IgG1κ) (unpublished), mouse anti-human ficolin-3 FCN334 (IgG1κ) (17), and  mouse 151 
anti-human  MASP-1/-3/MAP-1 8B3 (IgG1κ) (41,42).   152 
 153 
Production of recombinant proteins 154 
Recombinant MBL, ficolin-1, -2, -3, MASP-1, -2, and -3 were produced in our laboratory as 155 
previously described (43-45). In short, the proteins were expressed in CHO-DG44 cells cultivated 156 
in RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 157 
2 mM L-glutamine, and 200 nM methotrexate or by using serum-free medium Chinese hamster 158 
ovary (CHO) CD1 supplemented with 200 nM methotrexate. 159 
 160 
Preparation of monohydrate CC 161 
CC were prepared essentially as described by Samstad et al. (2014) (7). 100 mg ultrapure 162 
cholesterol was dissolved in 50 ml 1-propanol. 75 ml distilled water was added to the solution and it 163 
was left undisturbed for 15 min for the crystals to stabilize. The solution was centrifuged and the 164 
remaining 1-propanol was removed by evaporation. All steps were performed at room temperature 165 
(RT). The CC were resuspended in PBS/0.05% HSA and stored at 4C in the dark. 166 
 167 
Collection of serum samples 168 
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A pool of normal human serum (NHS) was obtained by drawing venous blood from six healthy 169 
donors (three male and three female donors) into dry glass vials with no additive. The blood 170 
samples were left at RT for 2 h, before the serum was collected by centrifugation at 3000xg for 15 171 
min, pooled, and stored at -80°C, awaiting further analysis. A pool of umbilical cord serum (UCS) 172 
was obtained from umbilical cord blood collected from three individuals. The blood samples were 173 
left at RT for 2 h, before the serum was collected by centrifugation at 3000xg for 15 min, pooled, 174 
and stored at -80°C, awaiting further analysis. Serum samples from a previously described MBL 175 
defect patient (46) and a C1q deficient patient (47) were used in the flow cytometry experiments.  176 
 177 
Flow cytometry 178 
Relevant controls were included routinely in all experiments, including negative controls samples 179 
(without protein/serum), isotype controls (mouse IgG1κ isotype control, mouse IgG2a isotype 180 
control, rabbit IgG isotype control, rat IgG1κ isotype control), and background control samples 181 
(containing no Ab or only primary or secondary Ab). Samples were analyzed by flow cytometry 182 
using a Gallios flow cytometer (Beckman Coulter) and data were analyzed using Kaluza software 183 
(Beckman Coulter). CC were gated as an uniform population on the forward site scatter, containing 184 
80-90% of all counts (see supplemental figure). 185 
 186 
Binding of MBL to CC 187 
CC (1.0 x 10^6 particles/ml) were incubated with 5% NHS or MBL defect serum or 0.25-4 µg/ml 188 
recombinant protein diluted in barbital buffer (5 mM barbital natrium, 145 mM NaCl, 2 mM CaCl2, 189 
1 mM MgCl2, pH 7.4) containing 0.5% heat inactivated fetal calf serum (FCS) (barbital/FCS) for 30 190 
min at 37C, shaking. The CC were washed in barbital/FCS after each step. Binding of MBL was 191 
detected with 0.5 µg/ml (recombinant protein) or 5 µg/ml (serum) mouse anti-human MBL mAb 192 
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131-10 (30 min at 4C), followed by 2.5 µg/ml FITC conjugated polyclonal goat anti-mouse Ab (20 193 
min at 4C). In some experiments CC were incubated with serum preincubated 5 min at RT with 10 194 
µg/ml MBL inhibitory mAb mouse anti-human MBL 3F8, or 10 µg/ml MBL binding mAb mouse 195 
anti-human MBL 1C10, 10 mM EDTA, 10 mM EGTA/Mg, 10 mM GlcNAc, 10 mM D-Mannose, 196 
or 10 mM D-(+)-Galactose.   197 
 198 
Binding of ficolin-1,ficolin-2, and ficolin-3 to CC 199 
CC (1.0 x 10^6 particles/ml) were incubated with 5% NHS or 0.25-4 µg/ml recombinant protein 200 
diluted in barbital/FCS for 30 min at 37C, shaking. The CC were washed in barbital/FCS after 201 
each step. Binding of ficolin-1, -2, or -3 was detected using 5 µg/ml mouse anti-human ficolin-1 202 
FCN106, 0.5 µg/ml (recombinant protein) or 5 µg/ml (serum) mouse anti-human  ficolin-2 mAb 203 
FCN219, or 5 µg/ml mouse anti-human ficolin-3 mAb FCN334 (30 min at 4C), followed by 2.5 204 
µg/ml FITC conjugated polyclonal goat anti-mouse Ab (20 min at 4C). In some experiments CC 205 
were incubated with serum preincubated 5 min at RT with 10 µg/ml ficolin-2 inhibitory mAb 206 
FCN212, 10 µg/ml acetylated BSA (AcBSA) prepared as described in Hein et al. (2010) (48), 10 207 
µg/ml BSA, 10 mM EDTA, 10 mM EGTA/Mg, 20 mM GlcNAc, 20 mM D-Mannose, or 20 mM D-208 
(+)-Galactose. 209 
 210 
Binding of MASPs/MAP-1 to CC 211 
CC (1.0 x 10^6 particles/ml) were incubated with 5% NHS diluted in barbital/FCS for 30 min at 212 
37C, shaking. The CC were washed in barbital/FCS after each step. Binding of MASP-1/-3/MAP-213 
1 was detected using 5 µg/ml mouse anti-human MASP-1/-3/MAP-1 8B3 and MASP-2 binding was 214 
detected using 5 µg/ml rat anti-human MASP-2 mAb 8B5 (30 min at 4C), followed by 2.5 µg/ml 215 
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FITC conjugated polyclonal goat anti-mouse Ab or 2 µg/ml FITC conjugated polyclonal rabbit anti-216 
rat Ab (20 min at 4C). 217 
 218 
Binding of MASPs in the presence of ficolin-2 or ficolin-3 219 
CC (1.0 x 10^6 particles/ml) were incubated with recombinant MASP-1 (4 µg/ml), MASP-2 (1 220 
µg/ml), or MASP-3 (1 µg/ml) or recombinant MASP-1, -2, or -3 in the presence of recombinant 221 
ficolin-2 (2 µg/ml) or ficolin-3 (2 µg/ml) diluted in barbital/FCS for 30 min at 37C, shaking. The 222 
CC were washed in barbital/FCS after each step. Binding of MASP-1 or MASP-3 was detected 223 
using 5 µg/ml mouse anti-human MASP-1/-3/MAP-1 mAb 8B3 (30 min at 4C), followed by 2.5 224 
µg/ml FITC conjugated polyclonal goat anti-mouse Ab (20 min at 4C). Binding of MASP-2 was 225 
detected using 5 µg/ml rat anti-human MASP-2 mAb 8B5 (30 min at 4C), followed by 2 µg/ml 226 
FITC conjugated polyclonal rabbit anti-rat Ab (20 min at 4C). 227 
 228 
Ficolin-2 mediated C4 deposition 229 
To assess ficolin-2 mediated complement activation CC (1.0 x 10^6 particles/ml) were incubated 230 
with recombinant ficolin-2 (2 µg/ml), recombinant MASP-2 (0.5 µg/ml) or a mixture of the proteins 231 
(30 min at 37C, shaking), followed by incubation with purified human C4 (10 µg/ml) (30 min at 232 
37C, shaking). The CC were washed in barbital/FCS after each step. Deposition of C4b on the CC 233 
was detected using 0.5 µg/ml polyclonal rabbit anti-human C4c Ab (30 min at 4C), followed by 2 234 
µg/ml FITC conjugated polyclonal goat anti-rabbit Ab (20 min at 4C).  235 
 236 
Complement activation on cholesterol crystals, when incubated with serum 237 
Complement activation from serum was assessed by incubating CC (1.0 x 10^6 particles/ml) with 238 
10% NHS, C1q deficient serum  with or without reconstitution with 10 µg/ml purified C1q, MBL 239 
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defect serum, or UCS diluted in barbital/FCS (30 min at 37C, shaking). The CC were washed in 240 
barbital/FCS after each step. Deposition of C5b-9 was detected using 2 µg/ml mouse anti-human 241 
complement component C5b-9 mAb, followed by 2.5 µg/ml FITC conjugated polyclonal goat anti-242 
mouse Ab (20 min at 4C). In some experiments CC were incubated with serum preincubated 5 min 243 
at RT with 50 µg/ml C5 inhibitor (eculizumab), 20 µM C3 inhibitory peptide (compstatin Cp40), 10 244 
µg/ml C1q inhibitory mAb mouse anti-human C1q clone 85, 5 µM MASP-1 inhibitor SGMI-1, 5 245 
µM MASP-2 inhibitor SGMI-2, 10 µg/ml MBL inhibitory mAb mouse anti-human MBL 3F8, or 10 246 
µg/ml MBL binding mAb mouse anti-human MBL 1C10.  247 
 248 
Binding of C1q, IgM, and IgG to CC 249 
CC (1.0 x 10^6 particles/ml) were incubated with 5% NHS, C1q deficient serum with or without 250 
reconstitution with 10 µg/ml purified C1q, MBL defect serum, or UCS diluted in barbital/FCS for 251 
30 min at 37C, shaking. The CC were washed in barbital/FCS after each step. Binding of C1q was 252 
detected with polyclonal rabbit anti-human C1q (30 min at 4C), followed by 2 µg/ml FITC 253 
conjugated polyclonal goat anti-rabbit Ab (20 min at 4C). Binding of IgM or IgG was detected 254 
using 1 µg/ml rabbit anti-human IgM or 0.1 µg/ml rabbit anti-human IgG, followed by 2 µg/ml 255 
FITC conjugated polyclonal goat anti-rabbit Ab (20 min at 4C). In some experiments CC were 256 
incubated with serum preincubated 5 min at RT with 10 µg/ml C1q inhibitory mAb mouse anti-257 
human C1q clone 85. 258 
 259 
Microscopy of CC 260 
Microscopy was performed using a Zeiss Axio Observer through a 63x/1.40 oil DIC Plan-261 
Apochromat objective. Imaging conditions were kept constant when acquiring images to be 262 
compared. Relevant controls were included routinely in all experiments, including negative controls 263 
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samples (without protein), isotype controls (mouse IgG1κ isotype control, mouse IgG2a isotype 264 
control), and background control samples (containing no Ab or only primary or secondary Ab). 265 
 266 
Binding of recombinant MBL and ficolin-2 267 
CC (2.0 x 10^6 particles/ml) were incubated with recombinant MBL (20 µg/ml) or ficolin-2 (8 268 
µg/ml) diluted in barbital/FCS for 30 min at 37C, shaking. The CC were washed in barbital/FCS 269 
after each step. Binding of MBL and ficolin-2 was detected with 5 µg/ml mouse anti-human MBL 270 
mAb 131-10 or 0.5 µg/ml mouse anti-human  ficolin-2 mAb FCN219 (30 min at 4C), followed by 271 
2.5 µg/ml FITC conjugated polyclonal goat anti-mouse Ab (20 min at 4C). CC were placed on 272 
slides by cytospin (centrifugation for 5 min at 300xg) and mounted with Glycergel mounting 273 
medium.  274 
 275 
Human carotid plaques  276 
Carotid plaques used for immunohistochemistry (IHC) and fluorescence microscopy were obtained 277 
from patients with carotid stenosis (49). Signed informed consent for participation in the study was 278 
obtained from all individuals. Plaque for paraffin sections was immediately after excision put in 279 
formalin for fixation before embedded in paraffin.  Plaque for frozen sections was taken and 280 
immediately put in Tissue-Tek O.C.T. compound and frozen at -80C.  281 
 282 
Haematoxylin Erythrosine (H&E) staining 283 
Haematoxylin Erythrosine (H&E) staining was prepared by a histological routine staining protocol. 284 
Briefly, formalin fixed, paraffin embedded sections of carotid plaques (4μm) were dried at 60 °C 285 
and stained in an automatic slide stainer (Sakura Tissue-Tek © Prisma™, USA). After 286 
deparaffinization and rehydration to water the slides were stained with H&E, and rinsed in water for 287 
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removal of excess dye. The sections were then dehydrated by adding ascending grades of ethanol 288 
and stained in Saffron, rinsed in several baths of absolute ethanol and cleared in Tissue Clear before 289 
cover slipping in Sakura Tissue-Tek © Glas™ automatic cover slipper.  290 
 291 
Indirect immunofluorescence of carotid sections  292 
Frozen-sections (5 µm) on SuperFrost Plus glass were dried for 10 min and washed in Dako 3006  293 
wash buffer before incubation in Serum Free Protein block for 30 min at RT. Mouse anti-human 294 
MBL mAb 131-01 (10 µg/ml),  mouse anti-human ficolin-2 mAb FCN219 (8 µg/ml),  and 295 
corresponding isotype controls were added and incubated over night at 4°C. After washing, the 296 
sections were incubated with Alexa647 anti-mouse IgG (3.3 µg/ml) for 60 min at RT before 297 
mounting in Mowiol 4-88.  The paraffin- and frozen sections were examined in an EVOS FL auto 298 
microscope (Thermo Fisher Scientific, USA). 299 
 300 
Immunohistochemistry of carotid sections 301 
Dried paraffin embedded sections of carotid plaques (4μm) were deparaffinized and rehydrated by 302 
increasing amounts of water in a Sakura Tissue-Tek © Prisma™. The sections were then stained in 303 
a Dako EnVision Plus autostainer for mouse antibodies according to the manufacturer protocol. 304 
Briefly, endogenous peroxidase activity was blocked by Peroxidase block and incubated with 305 
mouse anti-human MBL mAb 131-01 (10 µg/ml),  mouse anti-human ficolin-2 mAb FCN219, or an 306 
isotype control over night at 4°C followed by Polymer EnVision-HRP anti-mouse for 30 min. A 307 
DAB+ Chromogen solution was used to develop the color. The sections were then stained with 308 
Hematoxylin, dehydrated and prepared as described for the H&S staining.  309 
 310 
 311 
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Statistical analysis 312 
GraphPad Prism version 6 (Graphpad Software) was used for statistical analysis. Data are expressed 313 
as mean ± SEM. Statistical analysis was performed on three independent experiments using two-314 
tailed paired t-test. P < 0.05 was considered statistically significant. 315 
 316 
Ethical approval 317 
The study was approved by the regional health ethics committee in the Capital Region of 318 
Denmark (reference no. H2-2011-133). Carotid plaques used for IHC and fluorescence microscopy 319 
were obtained from patients with carotid stenosis (49). The protocols were approved by the 320 
Regional Committee for Medical and Research Ethics, South-East, Norway (reference no. S-0923a 321 
2009/6065).  322 
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Results 323 
Binding of lectin pathway pattern recognition molecules 324 
In the first set of experiments we investigated the binding of the PRMs from the LP to CC in vitro. 325 
No binding of ficolin-1 or ficolin-3 from NHS to CC was observed (Figure 1A, 1C). Ficolin-2 326 
bound strongly to CC, when incubated with NHS (Figure 1B) or recombinant ficolin-2 (Figure 1E 327 
and Figure 2). Ficolin-2 binding was inhibited when serum was preincubated with a ficolin-2 328 
inhibitory antibody (Ab) (p < 0.01) or specific ligands; AcBSA (p < 0.01) or GlcNAc (p < 0.05) 329 
(Figure 1B). Removal of calcium by addition of EDTA or EGTA/Mg had no inhibitory effect on 330 
ficolin-2 binding, but EDTA significantly (p<0.05) enhanced ficolin-2 binding. A strong binding of 331 
MBL to the CC was observed when incubated with NHS (Figure 1D) or recombinant MBL (Figure 332 
1F and Figure 2). MBL binding was significantly inhibited when serum was preincubated with an 333 
MBL inhibitory Ab (p < 0.01), specific ligands; GlcNAc (p < 0.01) or D-Mannose (p < 0.05), or in 334 
the absence of calcium (EDTA or EGTA/Mg) (p < 0.01) (Figure 1D). No binding of MBL was 335 
observed from MBL defect serum. These data show that both ficolin-2 and MBL bind specifically 336 
to CC incubated with serum or recombinant proteins.  337 
 338 
MASP binding and ficolin-2 mediated C4 deposition 339 
To further investigate the role of the lectin pathway, we looked into the binding of the MASPs and 340 
MAP-1 to CC incubated with NHS (Figure 3). Binding of MASP-1/-3/MAP-1 was detected using 341 
specific mouse mAb 8B3, recognizing the common heavy chain on all three molecules (41). A 342 
significant binding (p < 0.05) of native MASP-1/-3/MAP-1 to CC was observed (Figure 3A), 343 
whereas no binding of MASP-2 from NHS was observed (Figure 3B). To support this, we 344 
determined if the MASPs were able to form complexes with ficolin-2 on the surface of the CC 345 
(Figure 4). Recombinant MASPs bound to CC, and the binding of MASP-1 and MASP-3 was 346 
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significantly increased (p < 0.05) when co-incubated with ficolin-2, but not when co-incubated with 347 
the homologue PRM ficolin-3 (Figure 4A). Binding of MASP-2 was also increased when co-348 
incubated with ficolin-2, but the increase did not reach statistical significance (Figure 4A).  349 
We then determined if ficolin-2/MASP-2 complexes were able to activate complement by inducing 350 
C4 cleavage. Ficolin-2/MASP-2 complexes significantly increased C4 activation and deposition on 351 
the CC compared to CC incubated with C4 alone (p < 0.05), ficolin-2 followed by C4 (p < 0.01), or 352 
MASP-2 followed by C4 (p < 0.05) (Figure 4B). MASP-2 alone could be absorbed to the CC 353 
without ficolin-2 and enhance the C4 activation and deposition, but the increase did not reach 354 
statistical significance. These results indicate that the MASPs bind to CC and form functional 355 
complexes with ficolin-2. 356 
 357 
Localization of ficolin-2 and MBL in human carotid sections 358 
To confirm the physiological significance of the binding of ficolin-2 and MBL to the CC in vitro, 359 
we examined the deposition of ficolin-2 and MBL in human carotid plaques by IHC on paraffin 360 
embedded sections and immunofluorescence on frozen sections. Ficolin-2 and MBL were deposited 361 
in frozen sections of carotid plaques (Figure 5). Furthermore, immunohistochemically staining of 362 
MBL in carotid plaques showed colocalization of MBL and CC, visualized as MBL deposition 363 
around CC clefts (Figure 6). No staining was observed on any isotype controls. We were not able to 364 
detect the presence of ficolin-2 by IHC on paraffin sections, probably because of lack of epitope 365 
recognition of the ficolin-2 specific antibody. These results show that ficolin-2 and MBL are 366 
present in human carotid plaques and that MBL is localized around CC clefts.  367 
 368 
Classical and lectin pathway activation on CC 369 
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To further address the involvement of the LP in the CC induced complement activation, we 370 
measured the in vitro deposition of the complement activation product C5b-9 on CC after 371 
incubation with NHS, MBL defect serum, or C1q deficient serum by flow cytometry (Figure 7). In 372 
some experiments serum was preincubated with control Ab or different complement inhibitors; C3 373 
inhibitor (compstatin Cp40), C5 inhibitor (eculizumab), C1q inhibitory Ab, MASP-1 inhibitor, 374 
MASP-2 inhibitor, MBL control Ab, or MBL inhibitory Ab. C5b-9 deposition on CC was 375 
significantly inhibited with the C3 inhibitor compstatin Cp40 (p < 0.01) and completely removed by 376 
inhibition with the C5 inhibitor eculizumab (p < 0.01) (Figure 7A).  377 
 378 
C5b-9 deposition on CC from NHS was partly but significantly inhibited (p < 0.01) by the C1q 379 
inhibitory Ab (Figure 7B + 7C). The remaining complement activation in NHS was inhibited when 380 
combining the C1q inhibitory Ab with a LP inhibitor (MBL inhibitory Ab or MASP inhibitor) 381 
(Figure 7B and Figure 7C). The MBL inhibitory Ab in combination with the C1q inhibitory Ab 382 
significantly reduced (p < 0.01) the C5b-9 deposition on CC compared to inhibition with the C1q 383 
inhibitory Ab alone or the C1q inhibitory Ab and the MBL binding Ab control (Figure 7B). The 384 
MBL inhibitory Ab had no effect on the level of C5b-9 deposition on CC when incubated with NHS 385 
without the addition of the C1q inhibitory Ab. The MASP-1 inhibitor in combination with the C1q 386 
inhibitory Ab significantly reduced (p < 0.05) the level of C5b-9 deposition on CC when incubated 387 
with NHS compared to the C1q inhibitory Ab alone (Figure 7C). The MASP-1 inhibitor alone 388 
reduced the level of complement activation, but the decrease did not reach statistical significance. 389 
The MASP-2 inhibitor alone did not have an effect on the complement activation on CC, but when 390 
incubated in combination with the C1q inhibitory Ab, it decreased the level of C5b-9 deposition, 391 
but the decrease did not reach statistical significance (Figure 7C). In the MBL defect serum, 392 
complement activation on CC was significantly reduced (p < 0.01) by preincubating serum with the 393 
19 
 
 
 
C1q inhibitory Ab (Figure 7D). Complement activation on CC from C1q deficient serum was 394 
inhibited by the LP inhibitors as in NHS. The MBL inhibitory Ab significantly decreased (p < 0.05) 395 
the C5b-9 deposition on the CC compared to buffer (Figure 7E). Both the MASP-1 (p < 0.001) and 396 
the MASP-2 inhibitor decreased the complement deposition on CC from C1q deficient serum 397 
(Figure 7F), but the decrease did not reach statistical significance using the MASP-2 inhibitor. C1q 398 
reconstitution in the C1q deficient serum significantly increased (p < 0.05) the level of complement 399 
activation on CC to the level in NHS (Figure 7E). Inhibition of complement activation with the 400 
ficolin-2 inhibitory Ab alone or in combination with the C1q inhibitory Ab did not decrease the 401 
C5b-9 deposition in NHS (data not shown). Collectively, these data demonstrated that both the CP, 402 
initiated by C1q, and the LP, initiated by MBL, play important roles in the initiation of complement 403 
activation occurring on CC.  404 
 405 
C1q binding to CC is mediated by IgM 406 
It has previously been shown that C1q binds to CC (7). To confirm this in our system and to further 407 
study the binding of C1q, we examined the binding of C1q, IgM, and IgG to CC from NHS, C1q 408 
deficient, MBL defect serum, and UCS with low amounts of IgM. C1q bound strongly to the CC 409 
when incubated with serum (Figure 8). The C1q binding from NHS, MBL defect serum, and UCS 410 
was significantly inhibited (p < 0.05) with a C1q inhibitory Ab (Figure 8A). No binding of C1q was 411 
observed from C1q deficient serum. The C1q binding was reconstituted to the level of NHS when 412 
adding purified C1q to the C1q deficient serum. The C1q binding from UCS with low amounts of 413 
IgM was significantly lower (p < 0.01) than from NHS (Figure 8A). Supporting this, IgM binding to 414 
CC was significantly lower (p < 0.01) from UCS compared to NHS. IgM binding from C1q 415 
deficient serum was significantly increased (p < 0.05) compared to NHS. To investigate this, we 416 
inhibited C1q binding in NHS and reconstituted C1q in C1q deficient serum. When inhibiting C1q 417 
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binding in NHS, the detected level of IgM binding increased, whereas reconstitution of C1q in the 418 
C1q deficient serum significantly reduced (p < 0.05) the detected level of IgM binding to the level 419 
of NHS. Inhibition of C1q in MBL defect serum had almost the same effect as in NHS, whereas the 420 
level in UCS only slightly increased (Figure 8B). No binding of IgG to CC was observed (Figure 421 
8C). These data demonstrate that IgM but not IgG binds to CC when incubated with serum, and 422 
indicate that C1q binds indirectly to the CC via IgM.   423 
 424 
 425 
426 
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Discussion 427 
Crystalized cholesterol is found in early atherosclerotic lesions (1) and the presence of CC is 428 
regarded as a hallmark of atherosclerosis (50). CC activate the CP and the AP and induce 429 
complement dependent inflammasome activation and cytokine release (1,3-7). In the present study 430 
we report novel and important mechanisms by which CC induce complement activation, and to our 431 
knowledge, for the first time show that the lectin pathway is involved in the CC induced 432 
inflammatory response.  433 
 434 
Complement activation is involved in the development of atherosclerotic lesions. Complement 435 
activation to the level of C5b-9 has long been known to occur in atherosclerotic plaques (28,31) and 436 
several immunoglobulins, complement components and regulators are present in atherosclerotic 437 
lesions including IgG, IgM, C1q, and MBL (30,31). In C3- (26,51), C5- (52), C6- (29), and C1q-438 
deficient (32) mice or rabbit models, reduced complement activity affected atherosclerotic 439 
development. C6 complement deficiency was shown to protect against development of diet-induced 440 
atherosclerosis in rabbits (29), whereas total aortic atherosclerosis, determined by lipid staining, 441 
was greater in aortas from C3-deficient mice compared to controls (26). Taken together these 442 
results indicate that complement may have proatherogenic or antiatherogenic roles depending on the 443 
stage of atherosclerotic development. The role of the CP in atherosclerotic development has been 444 
demonstrated in a C1q deficient mouse model of atherosclerosis (32). C1q was found to reduce 445 
atherosclerosis development and mediate removal of apoptotic cells. However, deposition of C5b-9 446 
in mouse aortic root lesions was not abolished in the absence of C1q, suggesting involvement of the 447 
LP and/or the AP (32).  448 
 449 
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MBL is present and produced locally by myeloid cells in early experimental atherosclerotic lesions 450 
(35). MBL deposition has also been detected in late stage human atherosclerotic lesion, but no local 451 
expression of MBL was observed, suggesting a plasma origin MBL in late stage atherosclerosis 452 
(35). Our data demonstrate that MBL recognize CC, similar to those found in atherosclerotic 453 
lesions, in a specific and calcium dependent manner, leading to full complement activation and 454 
deposition of C5b-9 on the CC. This is surprising since MBL is regarded as a typical lectin, 455 
recognizing hydroxyl groups on carbohydrates. However, we suggest that MBL binds monohydrate 456 
CC via the CRD by recognizing hydroxyl groups exposed on the crystals. The binding of MBL to 457 
the CC demonstrated in this study was highly calcium dependent, and was inhibited by a specific 458 
inhibitor (an MBL inhibitory Ab) or known MBL ligands (GlcNAc or D-Mannose) strongly 459 
suggesting that this is a specific interaction via the CRD domain. No binding of MBL was detected 460 
from MBL defect serum, which in fact contains low molecular MBL unable to bind and mediate 461 
complement activation via the CRD domain (53). To support these findings we examined the 462 
presence of MBL in human carotid plaques. MBL was deposited in carotid plaques and localized 463 
around CC clefts. This confirms the physiological significance of the in vitro findings and 464 
demonstrates a potential role of the MBL mediated LP in the pathophysiology of atherosclerosis.  465 
Several population based studies, analyzing either MBL genotypes or resulting serum levels suggest 466 
a role for MBL in cardiovascular disease (34,54-60). However the results are contradictory, 467 
suggesting either a proatherogenic or antiatherogenic role of MBL in cardiovascular disease.  468 
Both MBL and C1q has been found to bind modified low density lipoprotein end enhance clearance 469 
by monocytes and macrophages (61,62). In early atherosclerotic lesions MBL may facilitate 470 
clearance of endogenous danger signals, such as late apoptotic or necrotic cells, cellular debris, low 471 
density lipoprotein, and CC which are associated with atherosclerosis development and plaque 472 
stability (20,21,63). In more advanced stages of atherosclerosis, MBL may have a proinflammatory 473 
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role; hence downregulation of MBL expression in late human lesions may illustrate control of 474 
complement activation and inflammation (35). 475 
 476 
Our data also demonstrate that ficolin-2 binds CC independent of calcium and that ficolin-2/MASPs 477 
complexes on CC are able to activate C4, leading to C4b deposition on the CC in vitro. 478 
Furthermore, ficolin-2 was deposited in human carotid plaques. Whether ficolin-2 mainly functions 479 
as an opsonin for phagocytosis independent of complement activation or participates in systemic 480 
complement activation as C1q and MBL remains to be established. No binding of ficolin-1 or 481 
ficolin-3 from serum to the CC was observed in our experiments. Ficolin-1 is mainly found on the 482 
surface of monocytes and granulocytes and in secretory granules of neutrophils and monocytes, but 483 
has been shown to circulate in serum in very low concentrations (14,40,64). Due to the low level of 484 
ficolin-1 in serum, the potential contribution of locally produced ficolin-1 in CC induced 485 
inflammation occurring in atherosclerosis remains to be investigated. The ficolins primarily 486 
recognize acetylated compounds, such as GlcNAc and acetylated BSA, via their fibrinogen like 487 
domain (18,19). Furthermore, ficolin-2 and ficolin-3 have been shown to bind a wide variety of 488 
exogenous and endogenous molecular patterns including several strains of encapsulated Gram-489 
positive bacteria (65,66), lipopolysaccharide from Gram-negative bacteria (67), DNA (22), 490 
mitochondria (68), and apoptotic cells (23). Ficolin-2 recognizes and binds ligands through four 491 
different binding groves with distinct binding properties (S1, S2, S3 and S4), giving ficolin-2 492 
unusual recognition versatility. In comparison, ficolin-1 and ficolin-3 only contain one binding 493 
grove (S1) (19,69). The more diverse binding capacity of ficolin-2 could explain the calcium 494 
independent binding to the CC. Calcium independent interactions of ficolin-2 have also been shown 495 
in recognition of pathogens like Aspergillus fumigatus and in interactions with endogenous ligands 496 
such as pentraxin-3 (70).  497 
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 498 
The results from the present study demonstrate an additive role of the MBL and the C1q mediated 499 
complement activation on CC. In NHS the level of complement activation was inhibited by a C1q 500 
inhibitory Ab, but the complement activation was not abolished. The remaining C5b-9 deposition 501 
was removed when inhibiting both C1q and MBL mediated complement activation.  Furthermore, 502 
we found deposition of ficolin-2 and MBL in human carotid plaques and MBL was colocalized to 503 
CC clefts. These data suggest that both LP and the CP play an important role in the CC mediated 504 
complement activation occurring in atherosclerotic lesions, and that complement inhibition could be 505 
an interesting target for treatment of cardiovascular disease. C1q has been shown to bind CC but the 506 
binding mechanism has previously been unknown (7). Our data confirm the binding of C1q to CC 507 
and further demonstrate that IgM, but not IgG binds to CC, and that the C1q binding is mediated by 508 
IgM.  509 
Complement activation on CC was inhibited less effective in our setup with the C3 inhibitor 510 
compstatin Cp40 compared to the C5 inhibitor eculizumab. This could partly be explained by the 511 
existence of a C3 bypass mechanism resulting in direct cleavage of C5 without activation of C3 as 512 
has been proposed by Huber-Lang et al. (71-73). 513 
 514 
In conclusion our study provides evidence for an important role for the lectin pathway in the 515 
inflammatory response induced by cholesterol crystals, and in particular emphasize the role of 516 
ficolin-2 and MBL in the cholesterol crystal mediated inflammation occurring during 517 
atherosclerotic plaque development.  518 
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Figure legends 775 
Figure 1: The PRMs ficolin-2 and MBL bind to CC. Binding of ficolin-1, ficolin-2, ficolin-3, 776 
and MBL to CC assessed by flow cytometry. A+C: No binding of ficolin-1 and ficolin-3 to CC was 777 
observed when incubating with 5% NHS. B: Histogram and bar plot showing ficolin-2 binding to 778 
CC when incubated with 5% NHS in the presence of buffer, control antibody (10 µg/ml), ficolin-2 779 
inhibitory antibody (10 µg/ml), ligands (10 µg/ml AcBSA, 10 µg/ml BSA, 20 mM GlcNAc, 20 mM 780 
D-Mannose, or 20 mM D-(+)-Galactose), EDTA (10 mM) or EGTA/Mg (10 mM). Ficolin-2 781 
binding was inhibited when serum was preincubated with a ficolin-2 inhibitory Ab (fic-2 inhi. Ab) 782 
or specific ligands; AcBSA or GlcNAc. EDTA or EGTA/Mg had no inhibitory effect on the ficolin-783 
2 binding, but EDTA significantly (p<0.05) enhanced the ficolin-2 binding to CC. D: Histogram 784 
and bar plot showing MBL binding to CC when incubated with 5% NHS in the presence of buffer, 785 
control antibody (10 µg/ml), MBL inhibitory antibody (10 µg/ml), ligands (10 mM GlcNAc, 10 786 
mM D-Mannose, or 10 mM D-(+)-Galactose) , EDTA (10 mM) or EGTA/Mg  (10 mM) or 5% 787 
MBL defect serum. MBL binding was inhibited when serum was preincubated with an MBL 788 
inhibitory Ab (MBL inhi. Ab), specific ligands; GlcNAc and D-Mannose, and in the absence of 789 
calcium (EDTA or EGTA/Mg). No MBL binding was observed from MBL defect serum (MBL def. 790 
S). E: Concentration dependent binding of recombinant ficolin-2 (0.25-4 µg/ml) to CC. F: 791 
Concentration dependent binding of recombinant MBL (0.25-4 µg/ml) to CC. 792 
Binding was assessed by median fluorescence intensity (MFI) and data are given as mean ± SEM 793 
(n=3). Histograms represent one of three independent experiments while columns represent three 794 
independent experiments. ns, non-significant, * p < 0.05, ** p < 0.01 compared to buffer or 795 
otherwise indicated. 796 
 797 
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Figure 2: Binding of recombinant ficolin-2 and MBL to CC. Binding of ficolin-2 (8 µg/ml) and 798 
MBL (20 µg/ml) to CC assessed by fluorescence microscopy. Imaging conditions were kept 799 
constant when acquiring images to be compared. Results are representative of three independent 800 
experiments.  801 
 802 
Figure 3: MASP-1/-3/ MAP-1 binding from serum. Binding of MASP-1/-3/MAP-1 or MASP-2 803 
to CC assessed by flow cytometry. A: Histogram and barplot showing significant MASP-1/-804 
3/MAP-1 binding to CC when incubated with 5% NHS. B: No binding of MASP-2 was observed 805 
when CC was incubated with 5% NHS. Binding was assessed by median fluorescence intensity 806 
(MFI) and data are given as mean ± SEM (n=3). Histograms represent one of three independent 807 
experiments while columns represent three independent experiments. ns, non-significant, * p < 0.05 808 
compared to control. 809 
 810 
Figure 4: Ficolin-2 mediates MASP binding and C4 deposition on CC. A: Binding of 811 
recombinant MASP-1 (4 µg/ml), MASP-2 (1 µg/ml), or MASP-3 (1 µg/ml) to CC assessed by flow 812 
cytometry. Binding of MASP-1, MASP-2, and MASP-3 was increased in the presence of 813 
recombinant ficolin-2 (2 µg/ml) but not in the presence of the homologue PRM ficolin-3 (2µg/ml). 814 
B: C4 activation and deposition induced by ficolin-2/MASP-2 complexes. CC were incubated with 815 
recombinant ficolin-2 (2 µg/ml) and/or recombinant MASP-2 (0.5 µg/ml), followed by incubation 816 
with purified human C 4 (10 µg/ml). MASP binding and C4 deposition was assessed by median 817 
fluorescence intensity (MFI) and data are given as mean ± SEM (n=3). Results are representative of 818 
three independent experiments. ns, non-significant, * p < 0.05, ** p < 0.01 compared to C4 (Figure 819 
4B) or otherwise indicated. 820 
 821 
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Figure 5: Ficolin-2 and MBL are present in human carotid plaques. Frozen sections of a human 822 
carotid plaque stained with H&E for histological examination (A+D), a ficolin-2 mAb (B+E), or an 823 
anti-MBL mAb (C+F). Representative sections of two positions in a carotid plaque are shown. 824 
Scale bars represent 200 µm.  825 
 826 
Figure 6: Colocalization of MBL and CC in human carotid plaques. Section of human carotid 827 
plaque immunohistochemically stained with an anti-MBL mAb (A+B) or an isotype control (C). 828 
Sections were counterstained with hematoxylin. A+B: MBL was present in human carotid plaques 829 
and localized around CC clefts. C: No staining was observed on the isotype control. Scale bars 830 
represent 200 µm (A) or 100 µm (B+C). 831 
 832 
Figure 7: CC activate the classical and the lectin complement pathway. Complement activation 833 
measured by C5b-9 deposition on CC, assessed by flow cytometry. 10% NHS (A-C), MBL defect 834 
serum (D) or C1q deficient serum (E-F) was incubated with CC in the presence of buffer, control 835 
antibody (10 µg/ml) or different complement inhibitors; C3 inhibitor (20 µM), C5 inhibitor (50 836 
µg/ml), C1q inhibitory Ab (C1q inhi. Ab) (10 µg/ml), MASP-1 inhibitor (MASP-1 inhi.) (5 µM), 837 
MASP-2 inhibitor (MASP-2 inhi.) (5 µM), MBL ctrl. Ab (10 µg/ml), or MBL inhibitory Ab (MBL 838 
inhi. Ab) (10 µg/ml). A: Complement activation on CC was significantly inhibited with the C3 839 
inhibitor (compstatin Cp40) and completely removed by inhibition with the C5 inhibitor 840 
(eculizumab). B+C: Complement activation in NHS was partly inhibited by the C1q inhi. Ab. The 841 
remaining complement activation in NHS was inhibited when combining the C1q inhi. Ab with a 842 
LP inhibitor (MBL inhi. Ab (B) or MASP inhi. (C)). D: Complement activation in MBL defect 843 
serum was inhibited by the C1q inhi. Ab. E+F: In the C1q deficient serum, complement activation 844 
was inhibited by the LP inhibitors, as in NHS. C5b-9 deposition was assessed by median 845 
42 
 
 
 
fluorescence intensity (MFI) and data are given as mean ± SEM (n=3). Results are representative of 846 
three independent experiments. ns, non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001. 847 
 848 
Figure 8: C1q binding to CC is mediated by IgM. C1q, IgM, and IgG binding to CC, when 849 
incubated with 5% NHS, C1q deficient serum (C1q def. S), MBL defect serum (MBL def. S), or 850 
UCS, measured by flow cytometry. A: Strong binding of C1q was observed when incubating CC 851 
with 5% NHS. C1q binding from C1q def. S, MBL def. S, and UCS was significantly lower than in 852 
NHS. No binding of C1q was observed from C1q def. S.  The C1q binding was reconstituted to the 853 
level of NHS when adding purified C1q (10 µg/ml) to the C1q def. S. Binding of C1q from NHS, 854 
MBL def. S, and UCS was completely inhibited with a C1q inhibitory Ab (C1q inhi. Ab) (10 855 
µg/ml). B: Detection of IgM binding to CC when incubated with serum was significantly increased 856 
in C1q def. S compared to NHS. When inhibiting C1q binding in NHS the detected level of IgM 857 
binding increased. Reconstitution of C1q in the C1q def. S significantly reduced the detected level 858 
of IgM binding to the level of NHS. Inhibition of C1q in MBL def. S had the same effect as in 859 
NHS, whereas the level in UCS only slightly increased. C: No binding of IgG to CC was observed. 860 
Binding was assessed by median fluorescence intensity (MFI) and data are given as mean ± SEM 861 
(n=3). Results are representative of three independent experiments. * p < 0.05, ** p < 0.01 862 
compared to NHS or otherwise indicated. 863 
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